Secukinumab
Cosentyx (secukinumab) is an antibody pharmaceutical. Secukinumab was first approved as Cosentyx on 2015-01-14. It is used to treat ankylosing spondylitis and psoriatic arthritis in the USA. It has been approved in Europe to treat ankylosing spondylitis, psoriasis, and psoriatic arthritis. The pharmaceutical is active against interleukin-17A.
| Trade Name | Cosentyx |
|---|---|
| Common Name | Secukinumab |
| Indication | ankylosing spondylitis, psoriasis, psoriatic arthritis |
| Drug Class | Monoclonal antibodies: interleukins as targets|monoclonal antibodies: fully human, neural indications |
